Indium (In111) Oxinate Curium Netherlands (Indium (111in) Oxine)

The oxine component transports the radioactive Indium‑111 into leukocytes ex vivo, forming a stable complex. After the labeled cells are re‑injected, they migrate to sites of active infection or inflammation, where the emitted gamma photons are detected by imaging equipment, producing diagnostic images.

The administered activity is determined by the prescribing physician based on the patient’s weight, clinical indication and imaging protocol. Dosing is individualized and should follow the radiopharmacy’s preparation guidelines and local regulatory requirements.

Indium-111 oxine is classified as a radiopharmaceutical with potential fetal radiation exposure, so it is generally avoided in pregnancy unless the diagnostic benefit outweighs the risk. Breastfeeding should be paused for an appropriate period after administration to prevent infant radiation exposure.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Indium-111 oxine is a well‑established leukocyte‑labeling agent offering high specificity for infection and inflammation. Compared with agents like Technetium‑99m HMPAO‑labeled leukocytes, Indium‑111 provides longer imaging windows due to its 2.8‑day half‑life, but involves higher radiation dose and requires gamma‑camera equipment capable of detecting its higher‑energy photons.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. It should be kept in the original container until use, and handled by trained personnel following radiation safety guidelines.

Indium-111 oxine is supplied as a sterile solution for injection. After leukocyte labeling in a radiopharmacy, the radiolabeled cells are administered intravenously under aseptic conditions, typically in a clinical setting equipped for radiopharmaceutical handling.

Serious risks include allergic reactions ranging from urticaria to anaphylaxis, radiation‑induced tissue injury, and rare hematologic effects such as severe neutropenia or hemolysis. Patients should be monitored for immediate hypersensitivity and radiation safety protocols must be observed.

Patients with known hypersensitivity to indium compounds, pregnant women unless absolutely necessary, breastfeeding mothers, and individuals with severe renal impairment or uncontrolled infection where leukocyte migration may be compromised should avoid this radiopharmaceutical.